Get the Stockscreener App
1,104.34
0.50%
-5.60
After Hours:
1104.10
-0.24
-0.02%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,104.34, with a volume of 3.09M.
It is down -0.50% in the last 24 hours and up +33.79% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,109.94
Open:
$1102
24h Volume:
3.09M
Relative Volume:
0.81
Market Cap:
$1.04T
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
54.62
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+5.22%
1M Performance:
+33.79%
6M Performance:
+54.73%
1Y Performance:
+39.91%
1-Day Range:
$1,098.10
$1,111.99
1-Week Range:
$1,038.00
$1,111.99
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,104.34 | 993.42B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.56 | 497.93B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.66 | 409.68B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.44 | 249.94B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
104.63 | 262.25B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Key facts: Eli Lilly co-develops ELUNATE®; Endowment sells 162,693 shares - TradingView
Eli Lilly and Company Stock (LLY) Opinions on $1 Trillion Market Cap Milestone - Quiver Quantitative
Eli Lilly’s (LLY) Endowment Becomes the Largest in the U.S. with $100 Billion of Assets - TipRanks
Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035 - GlobeNewswire Inc.
Will Eli Lilly and Company stock outperform growth indexesJuly 2025 Levels & Risk Controlled Swing Trade Alerts - BỘ NỘI VỤ
Eli Lilly Becomes First Healthcare Company Globally to Cross $1 Trillion Market Cap, Driven by Explosive GLP-1 Growth - eHealth Magazine
How Eli Lilly's weight-loss drugs propelled it to a $1 trillion valuation - fastcompany.co.za
Eli Lilly joins a very exclusive club - MarketScreener
JAMIE CARR: Pill popping puts Eli Lilly on a high - Business Day
Eli Lilly Becomes First Pharmaceutical To Hit $1 Trillion Valuation - InkFreeNews.com
Why Eli Lilly (LLY) Hit $1 Trillion as Obesity Drug Momentum Ignites Investor Optimism - Yahoo Finance
School board OKs tax abatement deal for Eli Lilly's $6.5B Houston-area plant - The Business Journals
Eli Lilly: $1 Trillion Built On One Drug Segment (LLY) - Seeking Alpha
Gimme shelter: Neurocrine, Lilly spared in CMS price cut fallout - BioWorld MedTech
JPMorgan Analyst Pounds the Table on Eli Lilly Stock (LLY) - TipRanks
Eli Lilly Crosses the $1 Trillion Line While the World Obsesses Over AI - Quasa.io
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026 - Finviz
Lilly rolling out direct-to-employer obesity drug coverage - Inside INdiana Business
Eli Lilly (LLY) Stock on November 26, 2025: Trillion‑Dollar Milestone, Pricing Shake‑Up and Stock‑Split Buzz - ts2.tech
Stock Split Watch: Is Eli Lilly Next? - AOL.com
Implications of Medicare Price Changes on Eli Lilly (LLY) - GuruFocus
Eli Lilly (LLY) Is Up 7.8% After Surpassing $1 Trillion Valuation on Obesity Drug Demand – Has The Bull Case Changed? - simplywall.st
BMO Launches New CDRs With Exposure to U.S. Stocks Including Microsoft, Eli Lilly, Exxon, Chevron and Robinhood - Yahoo! Finance Canada
Jim Cramer Discusses Eli Lilly (LLY) Touching the Trillion Dollar Market Value - MSN
JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating - Yahoo Finance
Major Shareholder Cashes In on Eli Lilly Stock! - TipRanks
Eli Lilly (LLY) Set to Gain as Medicare Negotiates Discounts on Competitor Drugs - GuruFocus
Eli Lilly endowment tops $100 billion By Investing.com - Investing.com Nigeria
Eli Lilly endowment tops $100 billion - Investing.com India
Lilly Endowment Is First to Hit $100 Billion Mark on Stock Surge - Bloomberg.com
LILLY ENDOWMENT INC Adjusts Holdings in Eli Lilly and Co - GuruFocus
LILLY ENDOWMENT INC Reduces Stake in Eli Lilly and Co - GuruFocus
Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025 - ts2.tech
Top analyst drops jaw-dropping price target on Eli Lilly stock - Yahoo Finance
Eli Lilly switches from Big 3 PBM to alternative transparent rival - Healthcare Brew
Eli Lilly Gets A Market Share Edge In The GLP-1 Race - Finimize
Lilly Redefines the Pharma Mega-Blockbuster - BioSpace
Eli Lilly’s new campaign depicts ups and downs of Alzheimer’s - Brand Innovators
Eli Lilly & Company (LLY) favors rally targeting 1188 - FXStreet
Redditors Are Buying Eli Lilly And Co (LLY) Ahead of Potential End of AI Trade. Here’s Why - Insider Monkey
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling - MarketBeat
Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30% - simplywall.st
How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals? - Barchart.com
Moneycontrol Pro Panorama | Lessons from Eli Lilly in corporate longevity - Moneycontrol
Major Shareholder Cashes Out Big on Eli Lilly & Co Stock! - TipRanks
Eli Lilly Joins the Trillion-Dollar Club, Powered by Blockbuster Weight-Loss Drugs - NAI500
Lilly to highlight breast cancer treatment advances at SABCS 2025 - Investing.com
Eli Lilly Vs Novo Nordisk Vs Others: Which Weight-Loss Stock Are Retail Traders Most Bullish On Over Next 5 Years? - Stocktwits
Health Care Stocks Edge Up As Biotech Shines And Eli Lilly Gets A Nod - Finimize
Inside Eli Lilly’s Alzheimer’s campaign blitz during holiday season - Campaign US
GLP-1 boom makes Eli Lilly the first $1 trillion pharma company - eMarketer
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):